Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Claudia Tandler; Jonas S. Heitmann; Tanja Michel; Maddalena Marconato; Simon U. Jaeger; Christian M. Tegeler; Monika Denk; Marion Richter; Melek Tutku Oezbek; Yacine Maringer; Sarah M. Schroeder; Nicole Schneiderhan‐Marra; Karl‐Heinz Wiesmüller; Michael Bitzer; Natalia Ruétalo; Michael Schindler; Christoph Meisner; Imma Fischer; Hans‐Georg Rammensee; Helmut R. Salih; Juliane S. Walz

doi:10.1016/j.ijid.2023.11.009

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Together, a single application of CoVac-1 elicits long-lived and broad SARS-CoV-2-specific T cell immunity, which further supports the current evaluation of our T cell activator in patients with congenital or acquired B-cell defects.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tandler et al. (2023) studied this question.

synapsesocial.com/papers/69d955795e5bcb4e3b835a21 https://doi.org/10.1016/j.ijid.2023.11.009

View Full Paper

Ask AI

Bookmark

Share

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Ask about this paper

Abstract

Discussion

Cite This Study

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading